Cortexyme to Present at Canaccord Genuity' s 41st Annual Growth Conference on August 11th

Rhea-AI Summary

Cortexyme, Inc. (Nasdaq: CRTX) is advancing its pivotal GAIN Trial aimed at treating mild to moderate Alzheimer's disease, with topline data expected in Q4 2021. Chris Lowe, COO and CFO, will participate in a virtual fireside chat at the Canaccord Genuity 41st Annual Growth Conference on August 11, 2021, at 3:00 p.m. ET. The event's webcast will be available on Cortexyme's Investor Calendar page and archived for 90 days. Cortexyme is focused on developing therapeutics for degenerative diseases, targeting the infectious pathogen P. gingivalis linked to Alzheimer’s pathology.

Cortexyme, Inc. (Nasdaq: CRTX), a company advancing a pivotal trial in Alzheimer's disease with topline data expected in the fourth quarter of 2021 and a growing pipeline of therapeutics for degenerative diseases, announced that Chris Lowe, the company’s chief operating officer and chief financial officer, will participate in a fireside chat at Canaccord Genuity' s 41^st Annual Growth Conference taking place virtually on Wednesday, August 11, 2021 at 3:00 p.m. ET / 12:00 p.m. PT.

A live webcast of the event will be accessible on the Investor Calendar page under the News & Events heading of Cortexyme’s investor website at ir.cortexyme.com. The webcast will be archived at that location for 90 days.

About Cortexyme

Cortexyme, Inc. (Nasdaq: CRTX) is a clinical stage biopharmaceutical company pioneering upstream therapeutic approaches designed to improve the lives of patients diagnosed with Alzheimer’s and other degenerative diseases. The company is advancing its disease-modifying pivotal GAIN Trial in mild to moderate Alzheimer's disease with top-line data expected in the fourth quarter of 2021, in addition to growing a proprietary pipeline of first-in-class small molecule therapeutics for Parkinson’s disease, periodontitis, and other diseases with high unmet clinical need. Cortexyme’s lead program targets a specific, infectious pathogen called P. gingivalis found in the brain and other organs and tied to degeneration and inflammation in humans and animal models. The company’s causation evidence for Alzheimer’s disease and the mechanism of its novel therapeutic has been independently replicated and confirmed by multiple laboratories around the world, as well as published in peer-reviewed scientific journals. To learn more about Cortexyme, visit www.cortexyme.com or follow @Cortexyme on Twitter.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210804005084/en/

FAQ

What is the purpose of Cortexyme's GAIN Trial for Alzheimer's disease?

The GAIN Trial is designed to test a disease-modifying therapy for patients with mild to moderate Alzheimer's disease, with topline data expected in Q4 2021.

When will Chris Lowe participate in the Canaccord Genuity Annual Growth Conference?

Chris Lowe will participate in the fireside chat on August 11, 2021, at 3:00 p.m. ET.

Where can I watch the webcast of Cortexyme's conference participation?

The webcast will be available on Cortexyme's Investor Calendar page at ir.cortexyme.com and will be archived for 90 days.

What does Cortexyme target in its Alzheimer's research?

Cortexyme targets the infectious pathogen P. gingivalis, which is linked to degeneration and inflammation in Alzheimer's patients.

What is Cortexyme's pipeline for degenerative diseases?

Cortexyme is developing a pipeline of first-in-class small molecule therapeutics for conditions including Parkinson's disease and periodontitis.